25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

RCE (Recce) Stock Analysis
Buy, Hold or Sell?

Let's analyze Recce together

I guess you are interested in Recce Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Recce’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Recce’s Price Targets

I'm going to help you getting a better view of Recce Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Recce Pharmaceuticals Ltd

I send you an email if I find something interesting about Recce Pharmaceuticals Ltd.

1. Quick Overview

1.1. Quick analysis of Recce (30 sec.)










1.2. What can you expect buying and holding a share of Recce? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
A$-0.03
Expected worth in 1 year
A$-0.13
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-0.10
Return On Investment
-31.0%

For what price can you sell your share?

Current Price per Share
A$0.31
Expected price per share
A$0.285 - A$0.41
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Recce (5 min.)




Live pricePrice per Share (EOD)
A$0.31
Intrinsic Value Per Share
A$-0.56 - A$-0.37
Total Value Per Share
A$-0.60 - A$-0.40

2.2. Growth of Recce (5 min.)




Is Recce growing?

Current yearPrevious yearGrowGrow %
How rich?-$6.1m-$1.6m-$4.5m-72.8%

How much money is Recce making?

Current yearPrevious yearGrowGrow %
Making money-$11.4m-$8.5m-$2.9m-26.0%
Net Profit Margin-257.8%-299.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Recce (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#804 / 874

Most Revenue
#361 / 874

Most Profit
#551 / 874

Most Efficient
#596 / 874
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Recce?

Welcome investor! Recce's management wants to use your money to grow the business. In return you get a share of Recce.

First you should know what it really means to hold a share of Recce. And how you can make/lose money.

Speculation

The Price per Share of Recce is A$0.31. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Recce.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Recce, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$-0.03. Based on the TTM, the Book Value Change Per Share is A$-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Recce.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.04-12.9%-0.04-12.9%-0.03-9.5%-0.03-10.1%-0.03-8.7%-0.02-5.3%
Usd Book Value Change Per Share-0.02-5.1%-0.02-5.1%-0.03-9.2%-0.02-7.3%0.00-1.3%0.00-0.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.4%0.000.8%0.000.4%
Usd Total Gains Per Share-0.02-5.1%-0.02-5.1%-0.03-9.2%-0.02-6.9%0.00-0.6%0.00-0.3%
Usd Price Per Share0.39-0.39-0.40-0.46-0.48-0.30-
Price to Earnings Ratio-9.80--9.80--13.65--15.52--22.11--19.90-
Price-to-Total Gains Ratio-24.95--24.95--14.11--22.73--2.35-41.19-
Price to Book Ratio-18.17--18.17--68.93--20.61-6.77-8.00-
Price-to-Total Gains Ratio-24.95--24.95--14.11--22.73--2.35-41.19-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.20181
Number of shares4955
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.00
Usd Total Gains Per Share-0.020.00
Gains per Quarter (4955 shares)-77.57-8.86
Gains per Year (4955 shares)-310.30-35.46
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-310-32046-82-45
20-621-63092-163-80
30-931-940138-245-115
40-1241-1250185-326-150
50-1551-1560231-408-185
60-1862-1870277-490-220
70-2172-2180323-571-255
80-2482-2490369-653-290
90-2793-2800415-734-325
100-3103-3110461-816-360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.012.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%4.06.00.040.0%5.07.00.041.7%
Dividend per Share0.00.01.00.0%1.00.02.033.3%3.00.02.060.0%3.00.07.030.0%3.00.09.025.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%4.06.00.040.0%5.07.00.041.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Recce Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.024-0.0240%-0.044+82%-0.035+44%-0.006-74%-0.003-86%
Book Value Per Share---0.033-0.0330%-0.009-73%-0.002-93%0.014-329%0.010-419%
Current Ratio--0.3410.3410%0.402-15%1.907-82%5.692-94%6.930-95%
Debt To Asset Ratio--2.4952.4950%2.013+24%1.570+59%1.011+147%0.759+229%
Debt To Equity Ratio----0%-0%0.085-100%0.143-100%0.296-100%
Dividend Per Share----0%-0%0.002-100%0.004-100%0.002-100%
Enterprise Value--161545003.000161545003.0000%174861497.600-8%199846559.000-19%215564898.080-25%147364480.156+10%
Eps---0.061-0.0610%-0.045-26%-0.048-21%-0.041-33%-0.025-59%
Ev To Ebitda Ratio---7.565-7.5650%-10.293+36%-14.077+86%-19.833+162%-19.394+156%
Ev To Sales Ratio--23.58423.5840%40.058-41%49.646-52%99.048-76%163.401-86%
Free Cash Flow Per Share---0.046-0.0460%-0.044-3%-0.040-11%-0.032-29%-0.019-57%
Free Cash Flow To Equity Per Share--0.0100.0100%-0.035+451%-0.019+292%0.003+256%0.001+570%
Gross Profit Margin--1.0701.0700%1.086-1%1.082-1%1.068+0%1.255-15%
Intrinsic Value_10Y_max---0.370----------
Intrinsic Value_10Y_min---0.565----------
Intrinsic Value_1Y_max---0.023----------
Intrinsic Value_1Y_min---0.045----------
Intrinsic Value_3Y_max---0.081----------
Intrinsic Value_3Y_min---0.146----------
Intrinsic Value_5Y_max---0.150----------
Intrinsic Value_5Y_min---0.258----------
Market Cap89395320.000-94%173023200.000173023200.0000%178444593.600-3%201860400.000-14%212484024.480-19%130796888.040+32%
Net Profit Margin---2.578-2.5780%-2.996+16%-3.045+18%-4.247+65%-7.966+209%
Operating Margin---3.171-3.1710%-3.941+24%-3.558+12%-4.926+55%-8.576+170%
Operating Ratio--3.1203.1200%3.969-21%3.892-20%5.176-40%8.823-65%
Pb Ratio-9.387+48%-18.168-18.1680%-68.929+279%-20.613+13%6.767-368%8.003-327%
Pe Ratio-5.062+48%-9.797-9.7970%-13.645+39%-15.524+58%-22.108+126%-19.904+103%
Price Per Share0.310-94%0.6000.6000%0.619-3%0.700-14%0.737-19%0.454+32%
Price To Free Cash Flow Ratio-6.798+48%-13.157-13.1570%-14.022+7%-18.419+40%-27.780+111%-25.369+93%
Price To Total Gains Ratio-12.891+48%-24.949-24.9490%-14.106-43%-22.728-9%-2.346-91%41.191-161%
Quick Ratio--0.3170.3170%0.350-9%1.882-83%5.662-94%6.908-95%
Return On Assets---2.773-2.7730%-5.117+85%-2.920+5%-2.143-23%-1.866-33%
Return On Equity----0%-0%-0.3640%-0.7240%-1.2630%
Total Gains Per Share---0.024-0.0240%-0.044+82%-0.033+36%-0.003-89%-0.001-94%
Usd Book Value---6199972.968-6199972.9680%-1685312.706-73%-445113.872-93%2703616.671-329%1944701.768-419%
Usd Book Value Change Per Share---0.016-0.0160%-0.029+82%-0.023+44%-0.004-74%-0.002-86%
Usd Book Value Per Share---0.021-0.0210%-0.006-73%-0.002-93%0.009-329%0.007-419%
Usd Dividend Per Share----0%-0%0.001-100%0.002-100%0.001-100%
Usd Enterprise Value--105165796.953105165796.9530%113834834.938-8%130100109.909-19%140332748.650-25%95934276.581+10%
Usd Eps---0.040-0.0400%-0.030-26%-0.031-21%-0.027-33%-0.016-59%
Usd Free Cash Flow---8561010.003-8561010.0030%-8284627.953-3%-7579194.588-11%-6076748.303-29%-3648565.631-57%
Usd Free Cash Flow Per Share---0.030-0.0300%-0.029-3%-0.026-11%-0.021-29%-0.013-57%
Usd Free Cash Flow To Equity Per Share--0.0060.0060%-0.023+451%-0.012+292%0.002+256%0.001+570%
Usd Market Cap58196353.320-94%112638103.200112638103.2000%116167430.434-3%131411120.400-14%138327099.936-19%85148774.114+32%
Usd Price Per Share0.202-94%0.3910.3910%0.403-3%0.456-14%0.480-19%0.295+32%
Usd Profit---11497775.814-11497775.8140%-8513401.722-26%-9054414.621-21%-7754128.183-33%-4709010.388-59%
Usd Revenue--4459203.5254459203.5250%2841755.616+57%3103088.282+44%2221088.961+101%1266674.527+252%
Usd Total Gains Per Share---0.016-0.0160%-0.029+82%-0.021+36%-0.002-89%-0.001-94%
 EOD+2 -6MRQTTM+0 -0YOY+13 -233Y+14 -255Y+11 -2810Y+14 -25

3.3 Fundamental Score

Let's check the fundamental score of Recce Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.062
Price to Book Ratio (EOD)Between0-1-9.387
Net Profit Margin (MRQ)Greater than0-2.578
Operating Margin (MRQ)Greater than0-3.171
Quick Ratio (MRQ)Greater than10.317
Current Ratio (MRQ)Greater than10.341
Debt to Asset Ratio (MRQ)Less than12.495
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-2.773
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Recce Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.058
Ma 20Greater thanMa 500.305
Ma 50Greater thanMa 1000.308
Ma 100Greater thanMa 2000.338
OpenGreater thanClose0.305
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis rapid infusion; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. Recce Pharmaceuticals has strategic partnership with Murdoch Children's Research Institute for development of the Neisseria gonorrhoeae, Mycobacterium abscessus, and Escherichia coli clinical trials; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Fundamental data was last updated by Penke on 2025-07-02 09:22:07.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Recce earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Recce to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -257.8%Β means thatΒ $-2.58 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Recce Pharmaceuticals Ltd:

  • The MRQ is -257.8%. The company is making a huge loss. -2
  • The TTM is -257.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-257.8%TTM-257.8%0.0%
TTM-257.8%YOY-299.6%+41.7%
TTM-257.8%5Y-424.7%+166.9%
5Y-424.7%10Y-796.6%+371.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-257.8%-92.7%-165.1%
TTM-257.8%-140.3%-117.5%
YOY-299.6%-196.4%-103.2%
3Y-304.5%-248.5%-56.0%
5Y-424.7%-343.4%-81.3%
10Y-796.6%-496.2%-300.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Recce is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Recce to theΒ Biotechnology industry mean.
  • -277.3% Return on Assets means thatΒ Recce generatedΒ $-2.77 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Recce Pharmaceuticals Ltd:

  • The MRQ is -277.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -277.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-277.3%TTM-277.3%0.0%
TTM-277.3%YOY-511.7%+234.4%
TTM-277.3%5Y-214.3%-63.0%
5Y-214.3%10Y-186.6%-27.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-277.3%-11.6%-265.7%
TTM-277.3%-11.6%-265.7%
YOY-511.7%-11.4%-500.3%
3Y-292.0%-11.8%-280.2%
5Y-214.3%-12.0%-202.3%
10Y-186.6%-13.7%-172.9%
4.3.1.3. Return on Equity

Shows how efficient Recce is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Recce to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Recce generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Recce Pharmaceuticals Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-72.4%+72.4%
5Y-72.4%10Y-126.3%+53.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.6%+13.6%
TTM--15.0%+15.0%
YOY--14.5%+14.5%
3Y-36.4%-16.9%-19.5%
5Y-72.4%-17.5%-54.9%
10Y-126.3%-19.9%-106.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Recce Pharmaceuticals Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Recce is operatingΒ .

  • Measures how much profit Recce makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Recce to theΒ Biotechnology industry mean.
  • An Operating Margin of -317.1%Β means the company generated $-3.17 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Recce Pharmaceuticals Ltd:

  • The MRQ is -317.1%. The company is operating very inefficient. -2
  • The TTM is -317.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-317.1%TTM-317.1%0.0%
TTM-317.1%YOY-394.1%+77.0%
TTM-317.1%5Y-492.6%+175.5%
5Y-492.6%10Y-857.6%+365.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-317.1%-229.2%-87.9%
TTM-317.1%-249.0%-68.1%
YOY-394.1%-208.5%-185.6%
3Y-355.8%-223.8%-132.0%
5Y-492.6%-346.1%-146.5%
10Y-857.6%-475.5%-382.1%
4.3.2.2. Operating Ratio

Measures how efficient Recce is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 3.12 means that the operating costs are $3.12 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Recce Pharmaceuticals Ltd:

  • The MRQ is 3.120. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.120. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.120TTM3.1200.000
TTM3.120YOY3.969-0.849
TTM3.1205Y5.176-2.056
5Y5.17610Y8.823-3.647
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1202.110+1.010
TTM3.1202.684+0.436
YOY3.9693.096+0.873
3Y3.8923.652+0.240
5Y5.1764.745+0.431
10Y8.8236.614+2.209
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Recce Pharmaceuticals Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Recce is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.34Β means the company has $0.34 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Recce Pharmaceuticals Ltd:

  • The MRQ is 0.341. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.341. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.341TTM0.3410.000
TTM0.341YOY0.402-0.061
TTM0.3415Y5.692-5.351
5Y5.69210Y6.930-1.238
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3413.661-3.320
TTM0.3413.846-3.505
YOY0.4024.140-3.738
3Y1.9074.688-2.781
5Y5.6925.746-0.054
10Y6.9306.147+0.783
4.4.3.2. Quick Ratio

Measures if Recce is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Recce to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.32Β means the company can pay off $0.32 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Recce Pharmaceuticals Ltd:

  • The MRQ is 0.317. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.317. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.317TTM0.3170.000
TTM0.317YOY0.350-0.033
TTM0.3175Y5.662-5.345
5Y5.66210Y6.908-1.246
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3172.826-2.509
TTM0.3173.182-2.865
YOY0.3503.786-3.436
3Y1.8824.311-2.429
5Y5.6625.703-0.041
10Y6.9086.454+0.454
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Recce Pharmaceuticals Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of RecceΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Recce to Biotechnology industry mean.
  • A Debt to Asset Ratio of 2.50Β means that Recce assets areΒ financed with 249.5% credit (debt) and the remaining percentage (100% - 249.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Recce Pharmaceuticals Ltd:

  • The MRQ is 2.495. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.495. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ2.495TTM2.4950.000
TTM2.495YOY2.013+0.482
TTM2.4955Y1.011+1.485
5Y1.01110Y0.759+0.251
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4950.329+2.166
TTM2.4950.349+2.146
YOY2.0130.331+1.682
3Y1.5700.340+1.230
5Y1.0110.349+0.662
10Y0.7590.379+0.380
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Recce is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Recce to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Recce Pharmaceuticals Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.143-0.143
5Y0.14310Y0.296-0.153
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.379-0.379
TTM-0.437-0.437
YOY-0.414-0.414
3Y0.0850.450-0.365
5Y0.1430.464-0.321
10Y0.2960.515-0.219
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Recce generates.

  • Above 15 is considered overpriced butΒ always compareΒ Recce to theΒ Biotechnology industry mean.
  • A PE ratio of -9.80 means the investor is paying $-9.80Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Recce Pharmaceuticals Ltd:

  • The EOD is -5.062. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.797. Based on the earnings, the company is expensive. -2
  • The TTM is -9.797. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.062MRQ-9.797+4.735
MRQ-9.797TTM-9.7970.000
TTM-9.797YOY-13.645+3.849
TTM-9.7975Y-22.108+12.311
5Y-22.10810Y-19.904-2.204
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.062-2.304-2.758
MRQ-9.797-2.080-7.717
TTM-9.797-2.564-7.233
YOY-13.645-3.764-9.881
3Y-15.524-3.773-11.751
5Y-22.108-6.193-15.915
10Y-19.904-6.833-13.071
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Recce Pharmaceuticals Ltd:

  • The EOD is -6.798. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.157. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -13.157. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.798MRQ-13.157+6.359
MRQ-13.157TTM-13.1570.000
TTM-13.157YOY-14.022+0.865
TTM-13.1575Y-27.780+14.623
5Y-27.78010Y-25.369-2.411
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.798-3.132-3.666
MRQ-13.157-2.705-10.452
TTM-13.157-3.666-9.491
YOY-14.022-4.405-9.617
3Y-18.419-5.059-13.360
5Y-27.780-8.477-19.303
10Y-25.369-9.304-16.065
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Recce is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -18.17 means the investor is paying $-18.17Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Recce Pharmaceuticals Ltd:

  • The EOD is -9.387. Based on the equity, the company is expensive. -2
  • The MRQ is -18.168. Based on the equity, the company is expensive. -2
  • The TTM is -18.168. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.387MRQ-18.168+8.781
MRQ-18.168TTM-18.1680.000
TTM-18.168YOY-68.929+50.762
TTM-18.1685Y6.767-24.934
5Y6.76710Y8.003-1.236
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.3871.953-11.340
MRQ-18.1681.843-20.011
TTM-18.1682.112-20.280
YOY-68.9292.441-71.370
3Y-20.6132.494-23.107
5Y6.7673.661+3.106
10Y8.0034.311+3.692
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Recce Pharmaceuticals Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Long-term Assets Other  000000000
Gross Profit  9214211,3421,5562,8971,2514,148-4,515-367



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets6,370
Total Liabilities15,893
Total Stockholder Equity-9,524
 As reported
Total Liabilities 15,893
Total Stockholder Equity+ -9,524
Total Assets = 6,370

Assets

Total Assets6,370
Total Current Assets5,136
Long-term Assets1,233
Total Current Assets
Cash And Cash Equivalents 4,415
Short-term Investments 208
Net Receivables 159
Other Current Assets 562
Total Current Assets  (as reported)5,136
Total Current Assets  (calculated)5,344
+/- 208
Long-term Assets
Property Plant Equipment 1,233
Other Assets 0
Long-term Assets  (as reported)1,233
Long-term Assets  (calculated)1,233
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities15,070
Long-term Liabilities824
Total Stockholder Equity-9,524
Total Current Liabilities
Short-term Debt 224
Accounts payable 3,967
Other Current Liabilities 10,878
Total Current Liabilities  (as reported)15,070
Total Current Liabilities  (calculated)15,070
+/-0
Long-term Liabilities
Capital Lease Obligations 811
Long-term Liabilities  (as reported)824
Long-term Liabilities  (calculated)811
+/- 12
Total Stockholder Equity
Common Stock54,839
Retained Earnings -70,076
Accumulated Other Comprehensive Income 5,713
Total Stockholder Equity (as reported)-9,524
Total Stockholder Equity (calculated)-9,524
+/-0
Other
Capital Stock54,839
Cash and Short Term Investments 4,415
Common Stock Shares Outstanding 177,100
Liabilities and Stockholders Equity 6,370
Net Debt -3,604
Net Invested Capital -9,524
Net Working Capital -9,933
Property Plant and Equipment Gross 2,023
Short Long Term Debt Total 811



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-30
> Total Assets 
32
80
148
4,987
3,721
1,465
1,144
922
3,244
21,682
12,624
2,556
6,370
6,3702,55612,62421,6823,2449221,1441,4653,7214,9871488032
   > Total Current Assets 
0
43
94
4,908
3,637
1,154
708
453
2,739
21,181
12,185
1,947
5,136
5,1361,94712,18521,1812,7394537081,1543,6374,90894430
       Cash And Cash Equivalents 
1
43
94
4,892
3,591
1,090
680
403
2,682
20,873
11,582
1,562
4,415
4,4151,56211,58220,8732,6824036801,0903,5914,89294431
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
20
47
208
20847200000000000
       Net Receivables 
0
0
0
16
40
60
21
37
41
245
583
91
159
15991583245413721604016000
       Other Current Assets 
0
0
0
16
6
64
8
13
16
62
20
295
562
56229520621613864616000
   > Long-term Assets 
0
37
54
79
83
311
435
469
505
501
439
608
1,233
1,233608439501505469435311837954370
       Property Plant Equipment 
32
37
54
79
83
311
435
469
505
501
439
608
1,233
1,2336084395015054694353118379543732
       Intangible Assets 
0
0
0
1
1
0
0
0
0
0
0
0
0
0000000011000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000
> Total Liabilities 
0
155
204
272
207
874
449
1,328
932
1,178
2,562
5,145
15,893
15,8935,1452,5621,1789321,3284498742072722041550
   > Total Current Liabilities 
0
155
204
266
195
690
416
1,273
885
1,078
2,447
4,850
15,070
15,0704,8502,4471,0788851,2734166901952662041550
       Short-term Debt 
0
0
0
0
7
161
3
737
83
113
75
148
224
2241487511383737316170000
       Short Long Term Debt 
0
0
0
0
7
161
3
0
0
0
0
0
0
000000316170000
       Accounts payable 
0
152
197
239
19
255
125
124
159
487
481
949
3,967
3,967949481487159124125255192391971520
       Other Current Liabilities 
0
2
7
27
169
435
288
412
643
478
1,891
3,753
10,878
10,8783,7531,89147864341228843516927720
   > Long-term Liabilities 
0
0
0
7
12
161
32
54
46
100
115
295
824
824295115100465432161127000
       Long term Debt Total 
0
0
0
0
0
161
0
0
0
14
0
103
0
010301400016100000
       Other Liabilities 
0
0
0
7
12
23
32
54
46
85
115
192
0
01921158546543223127000
> Total Stockholder Equity
32
-75
-56
4,714
3,514
590
695
-406
2,313
20,504
10,061
-2,589
-9,524
-9,524-2,58910,06120,5042,313-4066955903,5144,714-56-7532
   Retained Earnings -70,076-55,535-42,458-31,472-17,958-13,642-10,852-9,178-6,153-4,627-862-5900
   Accumulated Other Comprehensive Income 
0
0
0
2,959
2,248
1,533
1,516
1,663
1,805
8,678
8,551
8,835
5,713
5,7138,8358,5518,6781,8051,6631,5161,5332,2482,959000
   Capital Surplus 0000000000000
   Treasury Stock0000000000000



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.




5.6. Income Statements

Currency in AUD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue6,850
Cost of Revenue-7,217
Gross Profit-367-367
 
Operating Income (+$)
Gross Profit-367
Operating Expense-14,154
Operating Income-22,051-14,520
 
Operating Expense (+$)
Research Development0
Selling General Administrative5,870
Selling And Marketing Expenses1,241
Operating Expense14,1547,112
 
Net Interest Income (+$)
Interest Income187
Interest Expense-847
Other Finance Cost-0
Net Interest Income-660
 
Pretax Income (+$)
Operating Income-22,051
Net Interest Income-660
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-22,568-21,535
EBIT - interestExpense = -22,568
-22,568
-16,815
Interest Expense847
Earnings Before Interest and Taxes (EBIT)-21,721-21,721
Earnings Before Interest and Taxes (EBITDA)-21,354
 
After tax Income (+$)
Income Before Tax-22,568
Tax Provision-0
Net Income From Continuing Ops-17,662-22,568
Net Income-17,662
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses21,370
Total Other Income/Expenses Net-516660
 

Technical Analysis of Recce
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Recce. The general trend of Recce is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Recce's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Recce Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Recce Pharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.385 < 0.405 < 0.41.

The bearish price targets are: 0.285 > 0.285 > 0.285.

Know someone who trades $RCE? Share this with them.πŸ‘‡

Recce Pharmaceuticals Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Recce Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Recce Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Recce Pharmaceuticals Ltd. The current macd is -0.00347302.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Recce price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Recce. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Recce price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Recce Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartRecce Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Recce Pharmaceuticals Ltd. The current adx is 15.49.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Recce shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Recce Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Recce Pharmaceuticals Ltd. The current sar is 0.2856.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Recce Pharmaceuticals Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Recce Pharmaceuticals Ltd. The current rsi is 51.06. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Recce Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartRecce Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Recce Pharmaceuticals Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Recce price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Recce Pharmaceuticals Ltd Daily Stochastic Oscillator ChartRecce Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Recce Pharmaceuticals Ltd. The current cci is 31.75.

Recce Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartRecce Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Recce Pharmaceuticals Ltd. The current cmo is 7.28593471.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Recce Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartRecce Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Recce Pharmaceuticals Ltd. The current willr is -41.17647059.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Recce is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Recce Pharmaceuticals Ltd Daily Williams %R ChartRecce Pharmaceuticals Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Recce Pharmaceuticals Ltd. The current atr is 0.01917733.

Recce Pharmaceuticals Ltd Daily Average True Range (ATR) ChartRecce Pharmaceuticals Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Recce Pharmaceuticals Ltd. The current obv is -17,436,287.

Recce Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartRecce Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Recce Pharmaceuticals Ltd. The current mfi is 38.74.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Recce Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartRecce Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Recce Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Recce Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Recce Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.058
Ma 20Greater thanMa 500.305
Ma 50Greater thanMa 1000.308
Ma 100Greater thanMa 2000.338
OpenGreater thanClose0.305
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Recce with someone you think should read this too:
  • Are you bullish or bearish on Recce? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Recce? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Recce Pharmaceuticals Ltd

I send you an email if I find something interesting about Recce Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Recce Pharmaceuticals Ltd.

Receive notifications about Recce Pharmaceuticals Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.